COP1 and stroke disorder: In short, until 2015, two studies applying a model of TMCAO in rats supported that Cop-1 had potential in IS treatment, promoting neurogenesis and functional recovery, and reducing infarct volume in acute (seven days post-stroke) and chronic (60 days post-stroke) phases [48,49].